Long-term effect of obstructive sleep apnoea management on blood pressure in patients with resistant hypertension: the SARAH study
- PMID: 39060017
- DOI: 10.1183/13993003.00269-2024
Long-term effect of obstructive sleep apnoea management on blood pressure in patients with resistant hypertension: the SARAH study
Abstract
Background: There is a close relationship between obstructive sleep apnoea (OSA) and resistant hypertension (RH). However, studies assessing the long-term effect of diagnosing and treating OSA on blood pressure (BP) control in these patients are lacking.
Methods: To address this gap, we recruited 478 RH patients from hypertension units and followed them prospectively after they were screened for OSA through a sleep study. By performing 24-h ambulatory BP monitoring (ABPM) annually, the effect of OSA management was assessed.
Results: The patients had a median (interquartile range (IQR)) age of 64.0 (57.2-69.0) years, 67% were males and most were nonsleepy, with a median (IQR) apnoea-hypopnoea index (AHI) of 15.8 (7.9-30.7) events·h-1. The median (IQR) follow-up time was 3.01 (2.93-3.12) years. At baseline, severe OSA was associated with uncontrolled BP, nocturnal hypertension and a nondipper circadian BP pattern. Moreover, these patients had higher BP values during follow-up than did patients in the other groups. However, among patients with moderate and severe OSA, the management of sleep disordered breathing, including the implementation of continuous positive airway pressure treatment, was associated with a reduction in 24-h ABPM parameters, especially night-time BP values, at the 1-year follow-up. These benefits were attenuated over time and only subjects with severe OSA maintained an ABPM night-time reduction at 3 years. Furthermore, clinical variables such as uncontrolled BP, sex and age showed a predictive value for the BP response at 1 year of follow-up.
Conclusion: A favourable long-term decrease in BP was detected by diagnosing and treating OSA in a cohort of RH patients from hypertension units, but over time this decrease was only partially maintained in severe OSA patients.
Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: F. Barbé received research grants from Philips Respironics Inc. and ResMed (companies that develop products related to sleep apnoea), the Health Research Fund, the Spanish Ministry of Health, and the Spanish Respiratory Society to develop the SARAH study. Philips Respironics Inc. and ResMed partly funded the SARAH study but did not participate in nor were they involved in decisions regarding study development or the present manuscript. The remaining authors declare no competing interests.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous